On January 11, 2021 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), ("Onxeo" or "the Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage response (DDR), in particular against rare or resistant cancers, reported that its management team will attend the following key investor and scientific conferences in the coming months (Press release, Onxeo, JAN 11, 2021, View Source [SID1234575009]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright BioConnect 2021 Conference
January 11-14, 2021 (virtual conference)

For more information and to register, click here

Biomed Event
January 26-27, 2021 (virtual conference)

For more information and to register, click here

4TH Annual PARP & DDR Inhibitors Summit
January 26-28, 2021 (virtual conference)

For more information, click here

Edison Open House Global Healthcare 2021
January 26-28 2021 (virtual conference)

For more information and to register, click here

AACR Annual Meeting 2021
April 9-14, 2021 (virtual conference)